Experimental Ebola vaccines well tolerated, immunogenic in phase 2 study

(NIH/National Institute of Allergy and Infectious Diseases) Two investigational vaccines designed to protect against Ebola virus disease were well-tolerated and induced an immune response among 1,000 vaccinated participants in the Phase 2 randomized, placebo-controlled clinical trial called PREVAIL I. These findings were presented by one of the co-principal investigators, Fatorma Bolay, Ph.D., director of the Liberian Institute for Biomedical Research, this evening at the Conference on Retroviruses and Opportunistic Infections in Boston.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news